Fujifilm consolidates life sciences portfolio through strategic rebranding initiative
Fujifilm Corporation has announced a comprehensive rebranding of its life sciences subsidiaries, positioning the conglomerate as a unified provider of end-to-end pharmaceutical development solutions. The strategic restructuring affects two major subsidiaries and reflects the company’s substantial investment commitment to the biotechnology sector.
Major subsidiaries adopt new identities
FUJIFILM Irvine Scientific, the Santa Ana-based cell culture pioneer established in 1970, will operate under the new identity of FUJIFILM Biosciences. The company has evolved from its original cell culture media focus to encompass a comprehensive portfolio including discovery reagents, recombinant growth factors, specialty chemicals, and critical assay materials. The rebrand takes effect immediately, with legal entity changes scheduled for January 2026.
FUJIFILM Diosynth Biotechnologies, acquired by Fujifilm in 2011, transitions to FUJIFILM Biotechnologies whilst retaining its legal name. The contract development and manufacturing organisation operates facilities across Europe and the United States, providing process development through commercial supply capabilities.
Strategic integration under “Partners for Life” framework
The rebranding initiative operates under the “Partners for Life” umbrella, designed to simplify customer engagement across the pharmaceutical and biotechnology markets. Fujifilm has committed over US$10 billion through expansions and acquisitions over the past 15 years to establish these comprehensive capabilities.
“Under the ‘Partners for Life’ umbrella, our Life Sciences Group companies offer complete solutions to the pharmaceutical and biotechnology markets, aligning with both our strategic growth plans and commitment to innovation,” commented Toshihisa Iida, director, corporate vice president, general manager of Life Sciences Strategy Headquarters and Bio CDMO Division, FUJIFILM Corporation, Japan.
Enhanced collaborative positioning
The restructuring aims to leverage Fujifilm’s proprietary technologies, including artificial intelligence and sensing capabilities developed through its imaging and healthcare divisions. Brandon Pence, president and chief operating officer, FUJIFILM Biosciences, emphasised the company’s foundational principles: “Our foundation is based upon the core principles of putting our people first, transforming through innovation and science, and maintaining a commitment to unprecedented customer service.”
Lars Petersen, president and chief executive officer, FUJIFILM Biotechnologies, highlighted the collaborative benefits: “This closer coordination and united focus strengthens how we interact and deliver for our customers. Together, we offer deep knowledge and experience, speed, flexibility, and scientific rigour – critical elements in bringing complex biologics to life.”
